Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis

English version České info

Background:
Guidelines recommend intensive blood pressure (BP) lowering in patients at high risk. While placebo-controlled trials have demonstrated 22% reductions in coronary heart disease (CHD) and stroke associated with a 10-mmHg difference in systolic BP, it is unclear if more intensive BP lowering strategies are associated with greater reductions in risk of CHD and stroke. We did a systematic review to assess the effects of intensive BP lowering on vascular, eye, and renal outcomes.

Methods and Findings:
We systematically searched Medline, Embase, and the Cochrane Library for trials published between 1950 and July 2011. We included trials that randomly assigned individuals to different target BP levels.

We identified 15 trials including a total of 37,348 participants. On average there was a 7.5/4.5-mmHg BP difference. Intensive BP lowering achieved relative risk (RR) reductions of 11% for major cardiovascular events (95% CI 1%–21%), 13% for myocardial infarction (0%–25%), 24% for stroke (8%–37%), and 11% for end stage kidney disease (3%–18%). Intensive BP lowering regimens also produced a 10% reduction in the risk of albuminuria (4%–16%), and a trend towards benefit for retinopathy (19%, 0%–34%, p = 0.051) in patients with diabetes. There was no clear effect on cardiovascular or noncardiovascular death. Intensive BP lowering was well tolerated; with serious adverse events uncommon and not significantly increased, except for hypotension (RR 4.16, 95% CI 2.25 to 7.70), which occurred infrequently (0.4% per 100 person-years).

Conclusions:
Intensive BP lowering regimens provided greater vascular protection than standard regimens that was proportional to the achieved difference in systolic BP, but did not have any clear impact on the risk of death or serious adverse events. Further trials are required to more clearly define the risks and benefits of BP targets below those currently recommended, given the benefits suggested by the currently available data.

Please see later in the article for the Editors' Summary.

Vyšlo v časopise: Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. PLoS Med 9(8): e32767. doi:10.1371/journal.pmed.1001293
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001293

Souhrn

Zdroje

1. MacMahonS, PetoR, CutlerJ, CollinsR, SorlieP, et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765–774.

2. LewingtonS, ClarkeR, QizilbashN, PetoR, CollinsR (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913.

3. LawesCM, RodgersA, BennettDA, ParagV, SuhI, et al. (2003) Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 21: 707–716.

4. LawMR, MorrisJK, WaldNJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665.

5. TurnbullF (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535.

6. ManciaG, De BackerG, DominiczakA, CifkovaR, FagardR, et al. (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105–1187.

7. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43: S1–290.

8. WilliamsB, PoulterNR, BrownMJ, DavisM, McInnesGT, et al. (2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328: 634–640.

9. ChobanianAV, BakrisGL, BlackHR, CushmanWC, GreenLA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560–2572.

10. WhitworthJA (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21: 1983–1992.

11. ManciaG, LaurentS, Agabiti-RoseiE, AmbrosioniE, BurnierM, et al. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121–2158.

12. OgiharaT, KikuchiK, MatsuokaH, FujitaT, HigakiJ, et al. (2009) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: 3–107.

13. hypertension WgoCgftmo (2011) 2010 Chinese guidelines for the management of hypertension. Chin J Hypertens 19: 701–743.

14. Excellence NIfHaC (2011) Hypertension: clinical management of primary hypertension in adults. CG127. Available: http://guidanceniceorguk/CG127/Guidance/pdf/English

15. ArguedasJA, PerezMI, WrightJM (2009) Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev CD004349.

16. CushmanWC, EvansGW, ByingtonRP, GoffDCJr, GrimmRHJr, et al. (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575–1585.

17. VerdecchiaP, StaessenJA, AngeliF, de SimoneG, AchilliA, et al. (2009) Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374: 525–533.

18. OgiharaT, SarutaT, RakugiH, MatsuokaH, ShimamotoK, et al. (2010) Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 56: 196–202.

19. LiberatiA, AltmanDG, TetzlaffJ, MulrowC, GotzschePC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151: W65–94.

20. Woodward M (2005) Epidemiology: design and data analysis. 2nd edition. Boca Raton (Florida): Chapman and Hall/CRC Press.

21. EggerM, Davey SmithG, SchneiderM, MinderC (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.

22. TotoRD, MitchellHC, SmithRD, LeeHC, McIntireD, et al. (1995) “Strict” blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48: 851–859.

23. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317: 703–713.

24. HanssonL, ZanchettiA, CarruthersSG, DahlofB, ElmfeldtD, et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762.

25. EstacioRO, JeffersBW, GiffordN, SchrierRW (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 Suppl 2: B54–64.

26. SchrierRW, EstacioRO, EslerA, MehlerP (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61: 1086–1097.

27. WrightJTJr, BakrisG, GreeneT, AgodoaLY, AppelLJ, et al. (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288: 2421–2431.

28. KlahrS, LeveyAS, BeckGJ, CaggiulaAW, HunsickerL, et al. (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877–884.

29. SarnakMJ, GreeneT, WangX, BeckG, KusekJW, et al. (2005) The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142: 342–351.

30. RuggenentiP, PernaA, LorigaG, GanevaM, Ene-IordacheB, et al. (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365: 939–946.

31. EstacioRO, CollJR, TranZV, SchrierRW (2006) Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 19: 1241–1248.

32. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 31: 2115–2127.

33. WuhlE, TrivelliA, PiccaS, LitwinM, Peco-AnticA, et al. (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361: 1639–1650.

34. SchrierR, McFannK, JohnsonA, ChapmanA, EdelsteinC, et al. (2002) Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 13: 1733–1739.

35. AppelLJ, WrightJTJr, GreeneT, AgodoaLY, AstorBC, et al. (2010) Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918–929.

36. HayashiK, SarutaT, GotoY, IshiiM (2010) Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res 33: 1211–1220.

37. ReboldiG, GentileG, AngeliF, AmbrosioG, ManciaG, et al. (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29: 1253–1269.

38. FlackJM, NeatonJ, GrimmRJr, ShihJ, CutlerJ, et al. (1995) Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 92: 2437–2445.

39. BerlT, HunsickerLG, LewisJB, PfefferMA, PorushJG, et al. (2005) Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16: 2170–2179.

40. MesserliFH, ManciaG, ContiCR, HewkinAC, KupferS, et al. (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144: 884–893.

41. SleightP, RedonJ, VerdecchiaP, ManciaG, GaoP, et al. (2009) Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27: 1360–1369.

42. WaldDS, LawM, MorrisJK, BestwickJP, WaldNJ (2009) Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122: 290–300.

43. LawMR, WaldNJ, MorrisJK, JordanRE (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427.

44. FeldmanRD, ZouGY, VandervoortMK, WongCJ, NelsonSA, et al. (2009) A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 53: 646–653.